Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Next Previous
Trial Profile

Study to Evaluate the Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chiglitazar (Primary)
  • Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Chipscreen Biosciences

Most Recent Events

  • 24 May 2024 Status changed from recruiting to completed.
  • 28 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Oct 2023.
  • 28 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Oct 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top